<DOC>
	<DOCNO>NCT02875184</DOCNO>
	<brief_summary>This multicenter , prospective , non-interventional , observational single arm study . Two-hundred patient recruit Netherlands one year period . In case , decision treat patient apremilast make prior decision enter subject study . Treatment accord routine clinical practice base recommendation per Summary Product Characteristics ( SPC ) apremilast ( Otezla® ) . Each patient follow maximum 24 month .</brief_summary>
	<brief_title>A Study Apremilast Use Effectiveness Patients With Psoriatic Arthritis The Netherlands</brief_title>
	<detailed_description>The objective non-interventional study describe patient report outcome , effectiveness real-life use apremilast treatment patient psoriatic arthritis ( PsA ) .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Apremilast</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Inclusion Criter Patients ≥ 18 year age understand voluntarily sign informed consent form . Patients start treatment apremilast psoriatic arthritis . Refusal participate study . Language barrier complete questionnaire . Women pregnant breastfeeding . Hypersensitivity active substance excipients . Prior exposure apremilast Initiation apremilast treatment dermatologist psoriasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Psoriatic Arthritis</keyword>
	<keyword>Apremilast</keyword>
	<keyword>CC-10004</keyword>
</DOC>